Diarol

Quick links to important sections

Diarol

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Diarol

Quick Facts

Property Description
Active ingredient Repaglinide
Form Oral tablet
Pharmacological class Oral Antidiabetic Agent (Meglitinide)
Common use Management of Type 2 diabetes
Origin Synthetic

What Type of Medicine is Diarol (Repaglinide)?

Diarol is a prescription-only, synthetic oral antidiabetic agent used to help manage elevated blood sugar levels in adults diagnosed with Type 2 diabetes mellitus. Its active chemical substance is Repaglinide, an insulin secretagogue. This means that its primary function involves triggering the release of insulin from the pancreas. Repaglinide belongs to the pharmacological class of Meglitinide analogues and is administered orally, presenting as a tablet for systemic absorption. Chemically, Repaglinide is a carbamoylmethyl-benzoic acid derivative, confirming its distinct synthetic structure. It is recognized in clinical practice for its non-sulfonylurea chemical backbone, a differentiating factor from older secretagogues.


What is the General Purpose of Diarol?

The general purpose of Diarol is to contribute to effective anti-hyperglycemic therapy by providing targeted blood glucose-lowering action. It is designed to exploit the remaining functional capacity of the pancreatic beta-cells to secrete insulin. This action is clinically recognized for its flexibility, offering patients a focused approach to managing mealtime blood sugar spikes, a typical challenge in Type 2 diabetes. Repaglinide is characterized by a rapid onset and short duration of action, making it effective for post-meal glucose control. This rapid-acting characteristic is a key differentiating factor for Repaglinide. Diarol is a single-ingredient product that can be utilized either as monotherapy or integrated into a combination therapy regimen to help patients maintain better overall blood sugar control.

Regulatory References

  1. U.S. National Library of Medicine's MedlinePlus

What side effects are possible with Diarol?

Possible Side Effects and Safety Information

The safety profile of Diarol (Repaglinide) is primarily characterized by its effect on blood glucose levels. According to official regulatory documents, the most frequently encountered adverse reaction is hypoglycemia (low blood sugar), which is officially classified as a Very Common event.

Frequency and System-Organ Classes

The medicine's adverse effects are grouped by the physiological system affected. Gastrointestinal Disorders are also commonly reported, with abdominal pain and diarrhea classified as Common. Less frequent events include nausea and vomiting (Uncommon), and rare reports of visual disturbances and increased liver enzymes.

Classification Example Adverse Reaction
Very Common Hypoglycemia
Common Abdominal pain, Diarrhea

Serious Adverse Reactions and Safety Constraints

Serious hypoglycemic reactions, which may lead to loss of consciousness, are officially documented as Rare. Reports of severe hepatic dysfunction, such as jaundice or hepatitis, have occurred, emphasizing the importance of liver health. The risk of low blood sugar is generally considered greater at the start of treatment or during periods of dose escalation.

Repaglinide is formally contraindicated and should not be used in individuals with Type 1 diabetes mellitus, diabetic ketoacidosis, or severe hepatic impairment. This formal restriction establishes critical safety boundaries based on the drug's known metabolic profile and action.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory profile for Diarol (Repaglinide) overdose is defined by the risk of severe hypoglycemia (profound low blood sugar), which is an exaggerated effect of the medication. The FDA Prescribing Information and associated documents classify this condition as potentially life-threatening.

Documented Manifestations and Emergency Action

Classification Manifestation or Required Action
Documented Manifestations Symptoms of severe hypoglycemia, including seizures, coma, drowsiness, confusion, and tachycardia (rapid heart rate).
Required Emergency Action Immediate medical attention and hospitalization are required upon the manifestation of severe hypoglycemia or neurological symptoms.

Management of Repaglinide overdose is symptomatic and supportive, focusing on correcting the hypoglycemia. No specific antidote is described in the official labeling. Supportive measures documented in regulatory sources include the administration of oral glucose or sugar, Glucagon subcutaneous or intramuscular injection, or intravenous glucose infusion for unresponsive severe cases. Due to the risk of prolonged hypoglycemia, even asymptomatic patients may require continuous hospital monitoring and repeated blood glucose measurements for 24 hours, as documented by health authorities.

Therapeutic Uses of Diarol

Diarol (Repaglinide) is commonly used to help manage the fundamental symptoms related to systemic imbalance in adults diagnosed with Type 2 diabetes mellitus. This medication supports patients across several key therapeutic areas where additional symptomatic support is needed for managing blood sugar.

The medication plays a role in managing chronic hyperglycemia, addressing conditions marked by increased physiological stress when high blood sugar persists despite non-drug methods or other medications. Diarol is also commonly used in contexts involving the management of acute postprandial hyperglycemia (glucose surges after meals) and in clinical settings where patients require an adaptable treatment regimen due to irregular eating schedules.

The management of symptoms during periods of mealtime glucose spikes supports daily diabetes control. By assisting with the overall reduction of chronic high blood sugar and managing episodic symptom changes, the drug supports general well-being during symptomatic phases and may help patients cope more steadily with symptom fluctuations, contributing to easing the overall symptom load.


Quick Fact: Relief for Postprandial Symptoms
Primary Symptom Targeted Glucose surges after meals ( postprandial hyperglycemia)
Clinical Context Chronic management of T2DM where blood sugar control is insufficient
Patient Benefit Supports general well-being during fluctuating symptomatic patterns

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Diarol (Repaglinide) is officially indicated for use only in adults diagnosed with Type 2 diabetes mellitus (T2DM). Regulatory authorities strictly define the populations who must not use this medicine (contraindications) and those who require cautious use.


Populations Who Must Not Use Diarol

Use of Diarol is formally contraindicated by regulatory agencies in the following patient groups:

  • Patients with Type 1 diabetes mellitus or diabetic ketoacidosis (DKA).
  • Patients with a known hypersensitivity to repaglinide or any ingredient.
  • Patients with severe hepatic function disorder (severe liver disease).
  • Patients receiving concomitant use of Gemfibrozil (due to pharmacological risk).

Restricted and Special Population Use

Use of Diarol is not recommended for the pediatric population (under 18 years) or for older adults over 75 due to insufficient data on safety and efficacy in these age groups. It is also not recommended for women who are breastfeeding. Women who are pregnant may use the medicine only when the potential benefit is determined to justify the potential risk. Cautious use and dosage titration are required for patients with severe renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Diarol (Repaglinide) has officially documented interaction patterns that are classified based on pharmacokinetic and pharmacodynamic effects, according to regulatory labeling. These interactions structure specific restrictions on co-administration with other substances.


Official Interaction Restrictions

Classification Interacting Substance/Class Regulatory Constraint
Contraindicated Combination Gemfibrozil Must not be co-administered due to a significant, documented increase in Repaglinide plasma exposure.
Dose Restriction Required Clopidogrel, Cyclosporine Total daily dose of Repaglinide must be limited when co-administered to mitigate the risk of altered drug levels.
Avoid Combination NPH-insulin Co-administration is specifically not indicated in regulatory documentation.

Documented Interaction Mechanisms

Repaglinide is subject to pharmacokinetic interactions resulting from the inhibition of the CYP2C8 and CYP3A4 metabolic enzymes and the OATP1B1 hepatic uptake transporter. Co-administration with inhibitors of these pathways may lead to increased Repaglinide plasma concentrations. Conversely, enzyme inducers (e.g., Rifampicin) may decrease Repaglinide levels, potentially reducing its glucose-lowering effect.

Pharmacodynamic interactions are also documented, including the risk of an additive glucose-lowering effect when combined with other antidiabetic agents. Furthermore, substances such as non-selective Beta-blockers may mask the physical signs of hypoglycemia, complicating its recognition.

Mechanism of Action

How Diarol Works

Targeting Peripheral Mu-Opioid Receptors

Diarol exerts its action by functioning as a selective agonist on mu-opioid receptors (mu-opioid receptors) located predominantly on nerve endings within the intestinal wall. This targeted receptor binding inhibits the release of excitatory neurotransmitters, such as acetylcholine, from the enteric nerves . This biochemical event initiates the modulation of propulsive nerve signals.

Modulating Motility and Fluid Transport

The inhibition of signaling chemicals modifies the early molecular steps that govern systemic physiological outcomes. This mechanism primarily results in a reduction of the strong, rhythmic contractions (peristalsis) of the intestinal smooth muscle, thereby significantly prolonging the transit time of contents through the bowel. Additionally, the drug's mechanism engages pathways that influence fluid regulation by enhancing the reabsorption of water and electrolytes from the bowel contents back into the body, leading to the contents becoming less liquid.

Dosage and Administration Information

How to Use Diarol

Diarol (Repaglinide) is an oral medication with a precise administration schedule that is synchronized with food intake. The medication is available as tablets in strengths of 0.5 mg, 1 mg, and 2 mg.


Dosing and Administration Protocol

The fundamental principle of its use is preprandial timing. The tablet is administered via the oral route and is taken before each main meal—typically two to four times daily—to align its action with expected blood sugar surges. The protocol involves taking the dose within 15 minutes of the meal, allowing a window up to 30 minutes before eating.

Initial dosing ranges from 0.5 mg to 2 mg before each main meal, depending on initial HbA1c levels. The dose may be adjusted at intervals of at least one week to assess response, up to a maximum single dose of 4 mg. The maximum total daily dose is established at 16 mg.


Procedural Instructions and Special Populations

Administration includes specific procedural rules for meal variability: if a meal is skipped, the corresponding dose is also omitted, and an additional dose is added if an extra meal is consumed. For certain populations, such as adults with severe kidney impairment (creatinine clearance between 20 and 40 mL/min), a lower starting dose of 0.5 mg before each main meal is utilized. Safety and efficacy of this protocol have not been established for use in pediatric patients under 18 years of age.

Recent Clinical Evidence

Research evidence / Overview of studies for Diarol (Repaglinide)


Evidence for Use in Managing Type 2 Diabetes Mellitus

The research base for Diarol primarily includes Randomized Controlled Trials (RCTs), along with synthesized data from meta-analyses that combine results from several trials. These types of studies contribute to the broader evidence landscape exploring how Diarol was studied for managing high blood sugar in adults with Type 2 diabetes. The medication was evaluated in patients using it as a single agent (monotherapy) and as an add-on to other established therapies.

In these trials, researchers primarily monitored biomarkers related to blood sugar control. The main measure research examined was Glycated Hemoglobin ( HbA1c). Studies also looked specifically at acute blood glucose levels, including Fasting Blood Glucose (FBG) and Postprandial Blood Glucose (PPBG), which measures the glucose level immediately after meals. Findings from trials describe patterns where changes in these biomarkers were observed in patients treated with Diarol, including a focus on outcomes describing episodic or acute changes** in after-meal glucose surges.


Duration of Studies and Long-Term Follow-up

The follow-up durations were limited for many of the pivotal clinical trials for Diarol, with many studies running for 12 to 24 weeks and comparative trials often extending up to one year. Due to the limited length of the long-duration RCTs, long-term effects are not fully established and certainty remains low through direct evidence. The evidence concerning major long-term outcomes, such as the measurement of events related to cardiovascular outcomes, is largely based on scientific projections or statistical models that estimate these effects from the short-term HbA1c changes observed in some studies.


The Current Research Gaps and Uncertainties

A major research limitation is the lack of dedicated, large-scale Cardiovascular Outcomes Trials (CVOTs) that specifically track the influence of Diarol on long-term macrovascular complications. Furthermore, while Diarol was studied for use in patients with varying symptom burdens, comparative evidence is lacking for some of the complex combination regimens. The results apply only to the populations studied and reflect the specific conditions under which trials were conducted. Safety and effectiveness have not been established in the pediatric population (children and adolescents).

Key Studies & References Cardiovascular outcomes trials for type 2 diabetes: a narrative review of design and interpretation (Contextualizing CVOT gaps)

Frequently Asked Questions (FAQ)

Common questions about Diarol (FAQ)

Q: Are headaches a commonly reported side effect of Diarol?

Yes, regulatory documents list headache as one of the most common adverse reactions reported in clinical trials. This effect was observed in 5% or greater of patients taking the medicine in studies, based on official incidence reporting.

Q: Can Diarol cause feelings of tiredness or drowsiness?

Feelings of dizziness, drowsiness, or unusual tiredness are listed as possible symptoms associated with hypoglycemia (low blood sugar). Since low blood sugar is a common adverse reaction of this medication, these symptoms may be experienced due to that effect.

Q: Does taking Diarol affect a person's sleep patterns?

Regulatory safety information notes that nightmares can be an uncommon symptom associated with hypoglycemia (low blood sugar). This indicates that the medicine's effect on glucose levels could potentially relate to sleep disturbance.

Q: Is weight gain or loss a known side effect of Diarol?

Weight gain is listed in regulatory documents as a possible adverse reaction. Official summaries indicate that the drug class to which Diarol belongs is generally associated with a neutral effect on weight or a slight increase.

Q: Do the side effects of Diarol usually lessen or go away after a few days?

Official product information indicates that some mild adverse reactions, such as gastrointestinal symptoms (abdominal pain or diarrhea), may appear early in treatment. Regulatory summaries report that these effects have been observed to lessen or fade as the body adjusts to the medication over time.

Q: What is generally expected when someone discontinues the use of Diarol?

According to regulatory patient information, if this medication is discontinued and the patient's blood sugar is not controlled by lifestyle alone, a loss of glycemic control may occur. If this loss of control occurs, a change in medical management, such as the administration of insulin therapy, may be required.

Q: Is it permissible to consume alcohol while undergoing treatment with Diarol?

Regulatory documents state that alcohol consumption may affect blood glucose levels. This effect could potentially cause either dangerously low blood sugar (hypoglycemia) or high blood sugar (hyperglycemia). Official guidance emphasizes that alcohol use should be discussed with a healthcare professional.

Q: Does Diarol have interactions with common over-the-counter painkillers or cold medicines?

Regulatory patient counseling emphasizes the importance of informing a healthcare professional about all nonprescription medicines before use. This includes common over-the-counter painkillers (such as aspirin) and medicines for colds, coughs, or sinus problems, as they may alter the effects of Diarol.

Q: Are there any specific foods or beverages that are known to interact with Diarol?

Official regulatory documents and interaction checkers state that there are no known interactions between this medication and specific non-alcoholic foods or beverages.

Q: Why are people with certain types of heart problems advised against using Diarol?

The medicine is not indicated for use in combination with NPH insulin due to reports of serious cardiovascular adverse reactions observed with that specific combination. Separately, cardiovascular disease is also noted as a rare adverse reaction in some regulatory documents.

Q: How often do patients typically require check-ups or monitoring while on Diarol?

Regulatory documents require that the response to therapy be monitored by periodic measurements of blood sugar and HbA1 c levels. The need for more frequent check-ups and monitoring is often noted in regulatory guidance during the first few weeks of treatment or during any dose adjustment period.

Q: What is the purpose of the boxed or major warning label that may be on Diarol packaging?

The official label contains Warnings and Precautions that emphasize the primary safety concerns. These include the significant risk of hypoglycemia (low blood sugar) and the risk of serious cardiovascular adverse reactions when the medicine is used in combination with NPH insulin.

Q: How is Diarol typically supplied or packaged?

According to regulatory supply information, Diarol is manufactured and supplied as oral tablets in specific strengths (0.5 mg, 1 mg, and 2 mg). The medicine is commonly packaged in containers that align with quantities designed to fulfill standard prescription supply days.

Q: Can I take regular vitamins or dietary supplements at the same time as Diarol?

Official regulatory documents note the importance of informing a healthcare professional about all other products used, including vitamins, minerals, herbal products, and other supplements. This is necessary to review the potential for altered drug effects before starting treatment.

Q: Is Diarol generally appropriate for patients who are taking blood pressure medication?

Regulatory documents indicate that certain classes of blood pressure medications, specifically non-selective beta-blockers, are documented to interact with Diarol. This is because these medications may mask, or hide, the physical signs of low blood sugar, which is a common side effect of Diarol.

How should Diarol be stored and disposed of?

How to Store and Dispose of Diarol?

To ensure product stability and safety, Diarol must be stored according to official regulatory labeling. This typically requires storage below 25 C or 30 C and protection from moisture and light by keeping the medication in its original container with the lid tightly closed. It is mandatory to keep this and all medicines out of the sight and reach of children and pets to prevent accidental exposure.

For disposal of unused or expired Diarol, the best method is to use a community drug take-back program or mail-back envelope, if available. If no take-back option is accessible, the medication can be discarded in the household trash. To do this safely, remove the product from its original container, mix it with an undesirable substance (such as used coffee grounds or cat litter), place the mixture in a sealed plastic bag, and then throw the bag in the trash. Personal information on the packaging should be obscured or removed.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Diarol found in:

A-Z Index: